SCHEMBL497670

SCHEMBL497670

O=c1cc(-c2ccccc2)cn[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.52
CDK5 Q00535 4/20 0.52
CLK4 Q9HAZ1 4/20 0.52
DYRK1A Q13627 3/20 0.52
DYRK1B Q9Y463 2/20 0.52
CLK2 P49760 2/20 0.52
DYRK3 O43781 1/20 0.52
CLK1 P49759 1/20 0.52
CLK3 P49761 1/20 0.52
CDK5R1 Q15078 1/20 0.52
DYRK2 Q92630 1/20 0.52
HPGD P15428 1/20 0.50
CYP1A2 P05177 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NOTUM Q6P988 1/20 0.48
FGFR1 P11362 3/20 0.47
AKT1 P31749 2/20 0.47
AKT2 P31751 2/20 0.47
PTGS1 P23219 1/20 0.45
HTR3A P46098 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30015447 0.98 GSK3B (0.50) GSK3BCDK5CLK4DYRK1ADYRK1B
SCHEMBL1691424 0.80 HTR3A (0.45) NOTUMHTR3ARETMAP4K2HRH3
SCHEMBL27844309 0.80 FGFR1 (0.51) CDK5DYRK1ADYRK1BCDK5R1FGFR1
SCHEMBL5770101 0.80 MEN1 (0.46) HPGDNOTUMHTR3AHRH3KCNH2
SCHEMBL10537216 0.80 AOC3 (0.50) CYP1A2NOTUMFGFR1HTR3AMAP4K4
SCHEMBL18790699 0.80 CLK1 (0.49) GSK3BCDK5CLK4DYRK1ADYRK1B
SCHEMBL2652995 0.80 METAP2 (0.47) HPGDCSNK2A1KDM4EMAPTGABRA1
SCHEMBL22347150 0.80 MAP4K4 (0.49) MAP4K4MKNK2AURKANTRK1
SCHEMBL10538440 0.80 NOTUM (0.49) HPGDNOTUMHTR3ACDC7
SCHEMBL5562512 0.80 NOTUM (0.47) CLK4DYRK1BCYP1A2L3MBTL1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2157084-B1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE KOWA CO (JP) 2013-05-22 EP claimed
US-20100197698-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE KOWA COMPANY, LTD. (JP) 2010-08-05 US claimed
EP-2157084-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE Kowa Company, Ltd. (JP) 2010-02-24 EP claimed
EP-0933366-B1 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME NIKKEN CHEMICALS CO LTD (JP) 2005-04-06 EP claimed
US-6235739-B1 ANTIINFLAMMATORY AGENTS; ANTIHISTAMINES; SKIN DISORDERS NIKKEN CHEMICALS CO., LTD. (JP) 2001-05-22 US claimed
EP-0933366-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME Nikken Chemicals Company, Limited (JP) 1999-08-04 EP claimed
EP-0138344-A2 Pyridazinones as beta-adrenoceptor antagonists SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-04-24 EP claimed
JP-10059950-A None JP disclosed
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2026-05-26 US disclosed
US-12612371-B2 Sigma-1 receptor ligands and therapeutic uses thereof UNIVERSITE DE STRASBOURG (FR) 2026-04-28 US disclosed
EP-4076456-B1 SIGMA-1 RECEPTOR LIGANDS AND THERAPEUTIC USES THEREOF UNIV STRASBOURG (FR) 2024-05-01 EP disclosed
EP-4077310-B1 SIGMA-1 RECEPTOR LIGANDS AND USES THEREOF UNIV STRASBOURG (FR) 2024-05-01 EP disclosed
US-11807646-B2 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2023-11-07 US disclosed
WO-1997047604-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME NIKKEN CHEMICALS CO., LTD (JP) 1997-12-18 WO disclosed
US-4820819-A 5-phenyl-3[2H]-pyridazinone derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-04-11 US disclosed
US-4820819-A 5-phenyl-3[2H]-pyridazinone derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-04-11 US disclosed
US-4810705-A BENZODIAZEPINE DERIVATIVE ANTAGONISTS SANOFI (FR) 1989-03-07 US disclosed
US-4678786-A Pharmaceutical compositions having β-adrenoceptor antagonist activity employing pyridazinone derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1987-07-07 US disclosed
EP-0156734-A2 Triazolo[4,3-b]pyridazines, process for their preparation and pharmaceutical compositions containing them SANOFI S.A. (FR) 1985-10-02 EP disclosed
EP-0138344-A2 Pyridazinones as beta-adrenoceptor antagonists SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612371-B2 Sigma-1 receptor ligands and therapeutic uses thereof SIGMAR1, OPRL1, OPRM1 GSK3B 1323/4885CDK5 3379/4885CLK4 3748/4885
US-20100197698-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE SERPINE1, MMP1, PLAT GSK3B 1111/4885CDK5 506/4885CLK4 548/4885
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP1, USP10 GSK3B 1725/4885CDK5 506/4885CLK4 3230/4885
US-11807646-B2 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) USP19, USP16, USP18 GSK3B 1532/4885CDK5 1024/4885CLK4 2737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.